Ovarian cancer treatment and research at Dana-Farber
While ovarian cancer only accounts for 3 percent of all cancers diagnosed in women in the U.S., it causes more deaths than any other cancer of the female reproductive system. One of the reasons for this is that early stages of the disease, when it is easiest to treat, produce little or no symptoms, or symptoms that are often confused for other, less serious ailments. Ninety-three percent of women diagnosed with early stage ovarian cancer survive five years; unfortunately, only 19 percent of women are diagnosed at this stage. Roughly 30 percent of women diagnosed with advanced, late stage ovarian cancer survive more than five years, according to the American Cancer Society.
Related Links
- Treatment for ovarian cancer at Dana-Farber
- The Friends of Dana-Farber Cancer Risk and Prevention Clinic
- Clinical trials at Dana-Farber
Related Stories
- Myth Busters: The truth about the CA 125 test (March 18, 2008)
- Drugs given via catheter into the abdomen increase survival in women with ovarian cancer (Spring/Summer 2007)
- Diabetes drug dramatically boosts power of platinum chemotherapy (May 7, 2007)
- Searching for biomarkers of ovarian cancer (Spring/Summer 2006)
- Unexpected discovery may lower ovarian cancer risk (Fall/Winter 2005)
- Ramping up research: A multi-pronged attack on ovarian cancer (Summer 2005)
- WCP focuses new research on elusive ovarian cancer (Fall 2004)
- Dana-Farber researchers funded for assault on ovarian cancer (July 14, 2004)
- Stalking a stealthy disease: Hunting early warning signals in ovarian cancer (Spring 2004)
